SAB Biotherapeutics, Inc.
NASDAQ: SABSW0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Samuel J. Reich
- Employees
- 63
- Headquarters
- Sioux Falls, United States
- IPO year
- 2021
- Market cap
- $99.4K
- Website
- http://www.sabbiotherapeutics.com
Loading SABSW…
Loading profile data…Frequently asked questions about SABSW
What does SAB Biotherapeutics, Inc. (SABSW) do?
SAB Biotherapeutics, Inc. is a biopharmaceutical firm specializing in the development of immunotherapies. Their efforts are directed towards combating various health challenges, such as infectious and autoimmune diseases, as well as oncology. Among their notable therapeutic candidates are SAB-142, an anti-thymocyte globulin intended for Type 1 d...
Where does SABSW trade?
SAB Biotherapeutics, Inc. (SABSW) trades on the NASDAQ Global Market.
What sector is SABSW in?
SAB Biotherapeutics, Inc. (SABSW) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of SAB Biotherapeutics, Inc.?
Samuel J. Reich is the chief executive officer of SAB Biotherapeutics, Inc. (SABSW).
Where is SAB Biotherapeutics, Inc. headquartered?
SAB Biotherapeutics, Inc. is headquartered in United States.
Does SABSW pay a dividend?
SAB Biotherapeutics, Inc. (SABSW) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did SABSW go public?
SAB Biotherapeutics, Inc. (SABSW) completed its initial public offering in 2021.